- Home
- Publications
- Publication Search
- Publication Details
Title
Breast cancer
Authors
Keywords
-
Journal
LANCET
Volume 397, Issue 10286, Pages 1750-1769
Publisher
Elsevier BV
Online
2021-04-02
DOI
10.1016/s0140-6736(20)32381-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations
- (2020) Matthew S. Katz et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case
- (2020) Maria Teresa Vietri et al. European Journal of Medical Genetics
- Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening
- (2020) Christopher E. Comstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of Male Breast Cancer: ASCO Guideline
- (2020) Michael J. Hassett et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
- (2020) Matthias Guckenberger et al. LANCET ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature
- (2020) Igor Makhlin et al. Current Oncology Reports
- 139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
- (2020) R. Dent et al. ANNALS OF ONCOLOGY
- The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy
- (2020) Ross Mudgway et al. ANNALS OF SURGICAL ONCOLOGY
- Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
- (2020) Tawakalitu O. Oseni et al. ANNALS OF SURGICAL ONCOLOGY
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
- (2020) Hope S Rugo et al. Future Oncology
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
- (2020) Adrian Murray Brunt et al. LANCET
- Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis
- (2020) Elvire Pons-Tostivint et al. RADIOTHERAPY AND ONCOLOGY
- Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer
- (2020) Esther Pohl-Rescigno et al. JAMA Oncology
- Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy
- (2020) Giacomo Montagna et al. ANNALS OF SURGICAL ONCOLOGY
- Spatial location of local recurrences after mastectomy: a systematic review
- (2020) Orit Kaidar-Person et al. BREAST CANCER RESEARCH AND TREATMENT
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery
- (2020) Yibo Xie et al. Medical Dosimetry
- ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer
- (2020) Gerd Fastner et al. RADIOTHERAPY AND ONCOLOGY
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
- (2020) Ke-Da Yu et al. JAMA Oncology
- Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial
- (2020) Birgitte V. Offersen et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial
- (2020) Icro Meattini et al. JOURNAL OF CLINICAL ONCOLOGY
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Changes in Reoperation After Publication of Consensus Guidelines on Margins for Breast-Conserving Surgery
- (2020) M. Luke Marinovich et al. JAMA Surgery
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox
- (2020) Peter Dubsky et al. LANCET ONCOLOGY
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer
- (2019) Carol Forbes et al. Cancer Management and Research
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Michael Gnant et al. LANCET ONCOLOGY
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- (2019) Richard Gray et al. LANCET
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2019) R Condorelli et al. ANNALS OF ONCOLOGY
- West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
- (2019) Ulrike Nitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2019) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
- (2019) Andrea DeCensi et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
- (2019) David Krug et al. ANNALS OF SURGICAL ONCOLOGY
- Breast cancer, placenta and pregnancy
- (2019) Karolin Froehlich et al. EUROPEAN JOURNAL OF CANCER
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- (2019) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women’s lifestyle and health cohort
- (2019) Ula Nur et al. BMC CANCER
- Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
- (2019) Francesca Pellini et al. Breast Care
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
- (2019) Hyun-Ah Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
- (2019) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer
- (2019) Orit Kaidar-Person et al. RADIOTHERAPY AND ONCOLOGY
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- Winter is over: The use of Artificial Intelligence to individualise radiation therapy for breast cancer
- (2019) Philip M.P. Poortmans et al. BREAST
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer
- (2019) Janice S. Sung et al. RADIOLOGY
- When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?
- (2019) Ángel Montero et al. Current Oncology Reports
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
- (2019) Xin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
- (2019) Jack Cuzick et al. LANCET
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- (2019) Jennifer J Gao et al. LANCET ONCOLOGY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
- (2018) F Poggio et al. ANNALS OF ONCOLOGY
- Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
- (2018) Tracy-Ann Moo et al. ANNALS OF SURGICAL ONCOLOGY
- The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial
- (2018) Kari M. Rosenkranz et al. ANNALS OF SURGICAL ONCOLOGY
- Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
- (2018) Atilla Soran et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
- (2018) Matteo Lambertini et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
- (2018) Anne-Vibeke Lænkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
- (2018) Bernard Asselain et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Breast Cancer in Men
- (2018) Sharon H. Giordano NEW ENGLAND JOURNAL OF MEDICINE
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
- (2018) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature
- (2018) Richard Tancredi et al. ONCOLOGIST
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2018) Heikki Joensuu et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
- (2018) Viviana Galimberti et al. LANCET ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
- (2018) Janine M. Simons et al. ANNALS OF SURGERY
- Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study
- (2018) Jean-Marc Classe et al. BREAST CANCER RESEARCH AND TREATMENT
- Accelerated partial breast irradiation: Current status with a focus on clinical practice
- (2018) Fabiana A. Miranda et al. Breast Journal
- Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer
- (2018) S. R. Tee et al. BRITISH JOURNAL OF SURGERY
- Variation in the Use of Boost Irradiation in Breast-Conserving Therapy in the Netherlands: The Effect of a National Guideline and Cofounding Factors
- (2018) K. Schreuder et al. CLINICAL ONCOLOGY
- Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study
- (2018) Marissa C. van Maaren et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/RTOG 9804
- (2018) B. McCormick INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
- (2018) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
- (2018) Thomas Ruhstaller et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Eleftherios P Mamounas et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart toxicity from breast cancer radiotherapy
- (2018) Marc D. Piroth et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Preoperative breast radiation therapy: Indications and perspectives
- (2017) S.V. Lightowlers et al. EUROPEAN JOURNAL OF CANCER
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
- (2017) Armando E. Giuliano et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer
- (2017) Holm Eggemann et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
- (2017) Joanne L. Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
- (2017) Poornima Saha et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status
- (2017) Matteo Lambertini et al. JNCI-Journal of the National Cancer Institute
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
- (2017) Charlotte E Coles et al. LANCET
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
- (2017) Nicholas C Turner et al. LANCET
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- The global burden of women’s cancers: a grand challenge in global health
- (2017) Ophira Ginsburg et al. LANCET
- Radiation oncology enters the era of individualised medicine
- (2017) Philip Poortmans et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial
- (2017) Csaba Polgár et al. LANCET ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contemporary Hormonal Contraception and the Risk of Breast Cancer
- (2017) Lina S. Mørch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status
- (2017) Matteo Lambertini et al. JNCI-Journal of the National Cancer Institute
- Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer
- (2017) Eric Hahnen et al. JAMA Oncology
- Trends in Reoperation After Initial Lumpectomy for Breast Cancer
- (2017) Monica Morrow et al. JAMA Oncology
- Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force
- (2016) Joy Melnikow et al. ANNALS OF INTERNAL MEDICINE
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
- (2016) Mehra Golshan et al. BREAST CANCER RESEARCH AND TREATMENT
- Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
- (2016) Mary Pritzlaff et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
- (2016) Karin Ribi et al. JOURNAL OF CLINICAL ONCOLOGY
- Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology
- (2016) Lorenzo Livi et al. JOURNAL OF CLINICAL ONCOLOGY
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
- (2016) John F Forbes et al. LANCET
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis
- (2016) Chong Geng et al. PLoS One
- ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1
- (2016) Birgitte V. Offersen et al. RADIOTHERAPY AND ONCOLOGY
- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
- (2016) Ahmad Awada et al. JAMA Oncology
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates
- (2015) Mehra Golshan et al. ANNALS OF SURGERY
- Breast Cancer Screening for Women at Average Risk
- (2015) Kevin C. Oeffinger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
- (2015) Otto Metzger Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
- (2015) Jean-Francois Boileau et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
- (2015) Lucia Del Mastro et al. LANCET
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
- (2015) Rajendra Badwe et al. LANCET ONCOLOGY
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
- (2015) Ian H Kunkler et al. LANCET ONCOLOGY
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery
- (2015) Vratislav Strnad et al. RADIOTHERAPY AND ONCOLOGY
- Breast Cancer Diagnosed During Pregnancy
- (2015) Sibylle Loibl et al. JAMA Oncology
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
- (2014) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- Estrogen Receptor Mutations in Breast Cancer--New Focus on an Old Target
- (2014) C. V. Segal et al. CLINICAL CANCER RESEARCH
- Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate
- (2014) Philip Poortmans LANCET
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
- (2014) Mila Donker et al. LANCET ONCOLOGY
- Breast-Cancer Risk in Families with Mutations in PALB2
- (2014) Antonis C. Antoniou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
- (2013) M. Gnant et al. ANNALS OF ONCOLOGY
- Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer
- (2013) Zachary S. Zumsteg et al. ANNALS OF SURGICAL ONCOLOGY
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
- (2013) Judy C. Boughey JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial
- (2013) Mila Donker et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
- (2013) Jack Cuzick et al. LANCET
- The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
- (2013) Joanne S Haviland et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
- (2013) Thorsten Kuehn et al. LANCET ONCOLOGY
- Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
- (2013) Sarah C. Darby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab administration during pregnancy: a systematic review and meta-analysis
- (2012) Flora Zagouri et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
- (2012) Holm Eggemann et al. BREAST CANCER RESEARCH AND TREATMENT
- Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
- (2012) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of breast cancer during pregnancy: an observational study
- (2012) Sibylle Loibl et al. LANCET ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
- (2011) Martin Filipits et al. CLINICAL CANCER RESEARCH
- The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis
- (2011) Veronique K.M. Tan et al. JOURNAL OF SURGICAL ONCOLOGY
- Local treatment of metastatic cancer—killing the seed or disturbing the soil?
- (2011) Scott C. Morgan et al. Nature Reviews Clinical Oncology
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
- (2010) V. G. Vogel et al. Cancer Prevention Research
- Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study)
- (2010) Francesco Sardanelli et al. INVESTIGATIVE RADIOLOGY
- Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
- (2010) Christiane Kuhl et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)
- (2010) Csaba Polgár et al. RADIOTHERAPY AND ONCOLOGY
- Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature
- (2009) Jetske Ruiterkamp et al. BREAST CANCER RESEARCH AND TREATMENT
- Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld?
- (2008) Mariella Mannino et al. RADIOTHERAPY AND ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started